Table 3.
Patient characteristics by serum ferritin in Europe DOPPS (2009–15)
| Patient characteristic | All | Serum ferritin (ng/mL) |
|||
|---|---|---|---|---|---|
| <200 | 200–499 | 500–799 | ≥800 | ||
| Patients, n (%) | 6757 | 1443 (21) | 2676 (40) | 1636 (24) | 1002 (15) |
| Demographics | |||||
| Age (years), mean ± SD | 65.9 ± 14.9 | 64.6 ± 15.0 | 66.1 ± 15.2 | 66.8 ± 14.5 | 65.8 ± 14.6 |
| Sex (male), % | 62 | 68 | 62 | 60 | 55 |
| Race (black), % | 3 | 3 | 3 | 4 | 3 |
| Vintage (years), mean ± SD | 4.5 ± 5.8 | 4.5 ± 6.1 | 4.5 ± 5.7 | 4.5 ± 5.8 | 4.7 ± 5.7 |
| HD characteristics | |||||
| Catheter use, % | 28 | 31 | 28 | 28 | 27 |
| Single pool Kt/V, mean ± SD | 1.50 ± 0.33 | 1.44 ± 0.33 | 1.52 ± 0.34 | 1.50 ± 0.33 | 1.53 ± 0.32 |
| Anemia treatments (past 3–4 months) | |||||
| IV iron (with any dose), % | 79 | 73 | 81 | 81 | 77 |
| IV iron (mg/week) among treated, mean ± SD | 74 ± 47 | 72 ± 46 | 68 ± 44 | 77 ± 47 | 90 ± 53 |
| Bolusa dose of IV iron among treated, % | 22 | 23 | 17 | 22 | 31 |
| ESA (with any dose), % | 90 | 84 | 91 | 93 | 93 |
| ESA (1000 units/week) among treated, mean ± SD | 10 ± 8 | 11 ± 9 | 10 ± 8 | 9 ± 8 | 9 ± 8 |
| Transfused, % | 5 | 6 | 3 | 5 | 10 |
| Anemia labs, mean ± SD | |||||
| Ferritin (ng/mL) | 486 ± 380 | 116 ± 54 | 343 ± 85 | 628 ± 85 | 1, 166 ± 438 |
| TSAT (%) | 28.0 ± 12.5 | 22.7 ± 10.6 | 27.2 ± 10.7 | 29.9 ± 12.4 | 35.1 ± 15.3 |
| Hemoglobin (g/dL) | 11.5 ± 1.4 | 11.6 ± 1.5 | 11.5 ± 1.3 | 11.4 ± 1.3 | 11.3 ± 1.4 |
| Nutrition and inflammation markers, mean ± SD | |||||
| Body mass index (kg/m2) | 26.1 ± 5.5 | 26.1 ± 5.3 | 26.4 ± 5.6 | 25.9 ± 5.3 | 25.6 ± 5.5 |
| Normalized PCR (g/kg/day) | 1.00 ± 0.25 | 1.01 ± 0.25 | 1.00 ± 0.26 | 0.99 ± 0.23 | 0.99 ± 0.25 |
| Serum phosphorus (mg/dL) | 4.8 ± 1.5 | 5.0 ± 1.5 | 4.7 ± 1.4 | 4.8 ± 1.4 | 4.9 ± 1.5 |
| Serum bicarbonate (mEq/L) | 23.2 ± 3.3 | 22.7 ± 3.4 | 23.2 ± 3.2 | 23.2 ± 3.3 | 23.5 ± 3.5 |
| Serum potassium (mEq/L) | 5.0 ± 0.8 | 5.1 ± 0.8 | 5.0 ± 0.8 | 5.0 ± 0.8 | 5.1 ± 0.9 |
| Serum creatinine (mg/dL) | 8.0 ± 2.6 | 8.3 ± 2.8 | 8.0 ± 2.6 | 8.0 ± 2.6 | 7.7 ± 2.4 |
| Serum albumin (g/dL) | 3.72 ± 0.47 | 3.73 ± 0.47 | 3.72 ± 0.46 | 3.68 ± 0.48 | 3.72 ± 0.48 |
| WBC count (1000 cells/mm3) | 7.0 ± 2.2 | 7.0 ± 2.2 | 7.0 ± 2.3 | 7.0 ± 2.2 | 7.3 ± 2.3 |
| CRP (mg/L), median (IQR) | 6 (3–14) | 5 (2–12) | 5 (3–12) | 6 (3–14) | 8 (3–21) |
| Hospitalized in past 3–4 months, % | 17 | 17 | 16 | 18 | 19 |
| Comorbid conditions, % | |||||
| Coronary artery disease | 35 | 36 | 34 | 35 | 35 |
| Congestive heart failure | 19 | 17 | 19 | 18 | 20 |
| Cerebrovascular disease | 16 | 17 | 16 | 16 | 17 |
| Peripheral vascular disease | 30 | 34 | 30 | 28 | 30 |
| Other cardiovascular disease | 30 | 29 | 31 | 30 | 33 |
| Hypertension | 86 | 85 | 87 | 85 | 86 |
| Diabetes | 36 | 35 | 37 | 35 | 37 |
| Neurologic disease | 11 | 10 | 12 | 11 | 12 |
| Psychiatric disorder | 17 | 17 | 17 | 16 | 17 |
| Lung disease | 13 | 14 | 14 | 13 | 12 |
| Cancer (nonskin) | 17 | 15 | 16 | 19 | 19 |
| Gastrointestinal bleeding | 4 | 5 | 4 | 4 | 5 |
| Recurrent cellulitis, gangrene | 9 | 7 | 9 | 9 | 11 |
a
Defined as at least 1 month (of prior 3–4 months) with IV iron dose ≥500 mg.